This review will focus on both direct administration of exogenous neurotrophic factors and indirect methods of modifying endogenous neurotrophic factor levels in the central nervous system after stroke, and it will also examine the challenges involved in moving BDNF and NGF-related treatments from the bench to the clinic. This evidence concerns the gene NGF and stroke disorder.